Crestwood Advisors Group LLC Acquires 140 Shares of Eli Lilly and Company (NYSE:LLY)

Crestwood Advisors Group LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 0.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 35,686 shares of the company’s stock after purchasing an additional 140 shares during the quarter. Crestwood Advisors Group LLC’s holdings in Eli Lilly and Company were worth $31,616,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Global Wealth Management Investment Advisory Inc. increased its position in Eli Lilly and Company by 1.0% in the third quarter. Global Wealth Management Investment Advisory Inc. now owns 6,139 shares of the company’s stock worth $5,438,000 after buying an additional 58 shares in the last quarter. Heritage Investors Management Corp increased its holdings in Eli Lilly and Company by 13.5% in the 3rd quarter. Heritage Investors Management Corp now owns 1,149 shares of the company’s stock worth $1,018,000 after acquiring an additional 137 shares in the last quarter. Pittenger & Anderson Inc. increased its holdings in Eli Lilly and Company by 13.8% in the 3rd quarter. Pittenger & Anderson Inc. now owns 1,285 shares of the company’s stock worth $1,138,000 after acquiring an additional 156 shares in the last quarter. Amalgamated Bank raised its stake in Eli Lilly and Company by 0.3% during the 3rd quarter. Amalgamated Bank now owns 175,260 shares of the company’s stock worth $155,270,000 after acquiring an additional 556 shares during the period. Finally, United Advisor Group LLC purchased a new position in Eli Lilly and Company during the third quarter valued at approximately $532,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Down 0.2 %

Shares of NYSE LLY traded down $1.54 during mid-day trading on Tuesday, reaching $804.60. The company had a trading volume of 217,773 shares, compared to its average volume of 3,046,774. The stock has a market cap of $763.82 billion, a price-to-earnings ratio of 87.15, a price-to-earnings-growth ratio of 3.09 and a beta of 0.43. Eli Lilly and Company has a 52 week low of $561.65 and a 52 week high of $972.53. The business’s 50-day moving average is $908.15 and its 200-day moving average is $867.39. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The company had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business’s revenue was up 20.4% compared to the same quarter last year. During the same period last year, the business posted $0.10 earnings per share. Equities analysts expect that Eli Lilly and Company will post 13.23 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s payout ratio is 56.22%.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of recent analyst reports. Morgan Stanley reissued an “overweight” rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Citigroup boosted their price target on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a report on Friday, October 25th. Truist Financial upped their price target on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday, September 16th. Finally, Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Three analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $1,008.41.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.